Sterne, Kessler, Goldstein & Fox PLLC
Tyrosine alkoxyguanidines as integrin inhibitors
The present invention relates to novel tyrosine alkoxyguanidine compounds that are inhibitors of alpha V (&agr;v) integrins, for example &agr;v&bgr;3 and &agr;v&bgr;5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by &agr;v&bgr;3 and &agr;v&bgr;5 integrins, including conditions such as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, m and n are defined herein.
3-Dimensional Pharmaceuticals, Inc.
C A C A C C A C C C C C C C C C C A C A C A C
C07D A61P C07D A61P C07C C07D A61P C07D C07C C07C C07D C07C C07C C07C C07C C07C C07D A61P C07C A61P C07D A61P C07D
inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Yu Kai Bruce E.
Lee Tomczuk